Hepatitis B virus-associated nephropathy

被引:173
作者
Bhimma, R [1 ]
Coovadia, HM [1 ]
机构
[1] Univ KwaZulu Natal, Dept Paediat & Child Hlth, Nelson R Mandela Sch Med, ZA-4013 Congella, South Africa
关键词
hepatitis B virus; nephrotic syndrome; membranous nephropathy; proteinuria; interferon-alpha; 2b;
D O I
10.1159/000077065
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
A direct causal association between hepatitis B virus (HBV) infection and the development of nephropathy remains controversial. Epidemiological studies have shown that chronic carriage of HBV in some individuals ( particularly children) leads to the development of nephrotic syndrome with a strong male predominance, the commonest histological type being membranous nephropathy (MN). Spontaneous clearance of HBV antigens ( particularly the HBeAg) leads to abrogation of proteinuria. The isolation of immune complexes in the kidney suggests that the pathogenesis of the disease may have an immune-complex basis. Recent studies showing expression of HBV viral antigens in kidney tissue suggest direct viral-induced pathological alterations and chronic immunologic injury. Biosocial studies have detected no correlation between HBV carriage and proteinuria using both quantitative and qualitative urinary protein analysis. Genetic studies of HLA class I and II genes showed a predisposition to MN but no similar correlation in those with milder degrees of proteinuria. These findings suggest that milder proteinuria is unrelated to HBV carriage or genetic factors but the development of nephropathy, particularly MN, in patients with chronic HBV carriage (HBsAg and/or HBV DNA positive) is based on an interaction of virus and host factors. Although the natural history of the disease tends to remission with preservation of renal function, there is considerable morbidity and a small but significant mortality. Use of naturally occurring cytokines ( such as interferon-alpha2b) and other candidate therapies accelerates clearance of the virus and proteinuria. The most effective tool in reducing the incidence of the disease is the use of HBV vaccines. Copyright (C) 2004 S. Karger AG, Basel.
引用
收藏
页码:198 / 211
页数:14
相关论文
共 115 条
[1]   Successful treatment of hepatitis B virus (HBV)-associated membranoproliferative glomerulonephritis (MPGN) with alpha interferon [J].
Abbas, NA ;
Pitt, MA ;
Green, AT ;
Solomon, LR .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (05) :1272-1275
[2]  
ADHIKARI M, 1983, Annals of Tropical Paediatrics, V3, P17
[3]  
ALPER CA, 1984, NEW ENGL J MED, V321, P708
[4]   THE CHANGING EPIDEMIOLOGY OF HEPATITIS-B IN THE UNITED-STATES - NEED FOR ALTERNATIVE VACCINATION STRATEGIES [J].
ALTER, MJ ;
HADLER, SC ;
MARGOLIS, HS ;
ALEXANDER, WJ ;
HU, PY ;
JUDSON, FN ;
MARES, A ;
MILLER, JK ;
MOYER, LA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1990, 263 (09) :1218-1222
[5]  
Barin F, 1981, Prog Med Virol, V27, P148
[6]  
BEASLEY RP, 1981, LANCET, V2, P1129
[7]   The neglected role of type I interferon in the T-cell response: Implications for its clinical use [J].
Belardelli, F ;
Gresser, I .
IMMUNOLOGY TODAY, 1996, 17 (08) :369-372
[8]   Hepatitis B virus-associated nephropathy in black South African children [J].
Bhimma, R ;
Coovadia, HM ;
Adhikari, M .
PEDIATRIC NEPHROLOGY, 1998, 12 (06) :479-484
[9]   HLA associations with HBV carriage and proteinuria [J].
Bhimma, R ;
Coovadia, HM ;
Hammond, MG ;
Kramvis, A ;
Adhikari, M ;
Kew, MC .
PEDIATRIC NEPHROLOGY, 2002, 17 (09) :724-729
[10]   HLA class I and II in black children with hepatitis B virus-associated membranous nephropathy [J].
Bhimma, R ;
Hammond, MG ;
Coovadia, HM ;
Adhikari, M ;
Connolly, CA .
KIDNEY INTERNATIONAL, 2002, 61 (04) :1510-1515